Procter & Gamble Health Ltd

Stage 3 · Topping · week 7

As of 16 Oct 2026, Procter & Gamble Health is in Stage 3 — topping, where an uptrend loses steam, in week 7 (since 28 Aug 2026). It closed at ₹5,200, 24.8% below its 52-week high and below its 200-day average, which is falling. In Health Care, 40.6% of stocks are in Stage 2.

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. More about the company

₹5,200
+0.99% today
₹8,632 Cr · Mid cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is PGHL early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-24.8%
₹4,778.6 lo₹6,918.5 hi
24.8% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 7
1w13w26w
Week 7 — distribution, avoid new longs
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-6.7%
200 DMA: ₹5,573.1 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.59x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -2.7% vs MA50 -8.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-4.8%
3M
-23.5%
6M
+4.0%
YTD
-5.0%
1Y
-14.1%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 20w
S2 33w
S2 23w
S4 18w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 6w → S3 11w → S2 20w → S3 3w → S4 8w → S1 2w → S2 33w → S3 13w → S2 23w → S3 9w → S4 18w → S1 5w → S2 10w → S3 7w current
Total tracked: 168 weeks across 14 stage runs.
Scan Membership
Pullback Hunter
Latest: 2026-08-05
Prop Scan
Latest: 2026-08-05
Breakout Watch
Latest: 2026-06-22
46 appearances in last 60 days. First seen: 2024-07-10.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S3
Wk 7 · Vol 0.59x
2026-10-15S3
Wk 7 · Vol 0.58x
2026-10-14S3
Wk 7 · Vol 0.98x
2026-10-13S3
Wk 7 · Vol 0.56x
2026-10-12S3
Wk 6 · Vol 0.36x
2026-10-09S3
Wk 6 · Vol 0.50x
2026-10-08S3
Wk 6 · Vol 0.39x
2026-10-07S3
Wk 6 · Vol 0.73x
2026-10-06S3
Wk 6 · Vol 1.25x
2026-10-05S3
Wk 5 · Vol 0.61x
2026-10-01S3
Wk 5 · Vol 0.60x
2026-09-30S3
Wk 5 · Vol 0.76x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹5,590.8
200 DMA
₹5,573.1
52W High
₹6,918.5
52W Low
₹4,778.6
5D Low
₹5,149
Resistance levels (recent highs)
20d High
₹5,696
60d High
₹6,784
120d High
₹6,918.5
250d High
₹6,918.5
Next resistance
+9.5%
to 20d High
Ask the Market AI about PGHLAsk →
P/E (TTM)
31.8
Forward 33.0
Earnings Growth (YoY)
-14.6%
Revenue +20.7%
Dividend Yield
3.84%
P/B 16.7
About this companyHealth Care· Pharmaceuticals

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.